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Abstract
Background: Experimental reproducibility in mouse models is impacted by both genetics and environment. The
generation of reproducible data is critical for the biomedical enterprise and has become a major concern for the
scientific community and funding agencies alike. Among the factors that impact reproducibility in experimental
mouse models is the variable composition of the microbiota in mice supplied by different commercial vendors.
Less attention has been paid to how the microbiota of mice supplied by a particular vendor might change over
time.
Results: In the course of conducting a series of experiments in a mouse model of malaria, we observed a profound
and lasting change in the severity of malaria in mice infected with Plasmodium yoelii; while for several years mice
obtained from a specific production suite of a specific commercial vendor were able to clear the parasites
effectively in a relatively short time, mice subsequently shipped from the same unit suffered much more severe
disease. Gut microbiota analysis of frozen cecal samples identified a distinct and lasting shift in bacteria populations
that coincided with the altered response of the later shipments of mice to infection with malaria parasites. Germ-
free mice colonized with cecal microbiota from mice within the same production suite before and after this change
followed by Plasmodium infection provided a direct demonstration that the change in gut microbiota profoundly
impacted the severity of malaria. Moreover, spatial changes in gut microbiota composition were also shown to alter
the acute bacterial burden following Salmonella infection, and tumor burden in a lung tumorigenesis model.
Conclusion: These changes in gut bacteria may have impacted the experimental reproducibility of diverse research
groups and highlight the need for both laboratory animal providers and researchers to collaborate in determining
the methods and criteria needed to stabilize the gut microbiota of animal breeding colonies and research cohorts,
and to develop a microbiota solution to increase experimental rigor and reproducibility.
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Background
Although the self-correcting nature of science is a virtue,
recent years have experienced a growing awareness and
concern across diverse scientific disciplines that pub-
lished studies are not always reproducible [1, 2]. Lack of
reproducibility slows the advancement of science, erodes
public confidence in science, and impedes the
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development of new therapeutics [1–3]. A Nature survey
of 1576 scientists identified that 70% of researchers have
failed to reproduce a published result [2]. A number of
reports and editorials from journals, including Science
and Nature and the National Institutes of Health, have
identified procedures to improve reproducibility [3–6].
The Nature survey found that respondents were less in-
clined to attribute variability in reagents as a contributor
to irreproducibility [2]. Yet, there is a growing recogni-
tion that mouse studies that fail to control for differ-
ences in murine gut microbiota are indeed factors that
impact reproducibility of mouse studies [7–9].
Differences in gut microbiota among genetically simi-
lar mice obtained from different commercial vendors
were originally reported 30 years ago [10]. This report
provided a basic characterization of differences in gut
bacteria without any association to a biological effect. As
our appreciation of the effect of gut microbiota on host
physiology has rapidly grown over the previous decade,
so have the number of publications that identified differ-
ences in gut microbiota among genetically similar mice
from different vendors and that these differences can
have profound impacts on various biological processes
[11–20]. Moreover, genetically identical mice within the
same institution can have differences in gut microbiota
that alter host biology [21–24].
In contrast to the known differences in gut bacteria in
mice from different vendors and genetically identical
mice within the same institution, there is much less
known regarding variation in gut bacteria from a specific
vendor over time. In one study that sampled fecal pellets
from a total of forty-six 129X1/SvJ mice over time and
among four separate shipments from Jackson Laborator-
ies, only 18% of the observed variation in bacteria popu-
lations among all samples was explained by shipment
groups [25]. Indeed, taxonomic plots at the phylum level
showed similar taxonomic abundances between ship-
ments, with the greatest variability observed between in-
dividual mice independent of the shipment group.
Although variation between shipments was noted, these
were not temporally consistent differences (i.e., ship-
ments I and III were similar to one another while ship-
ments II and IV were similar to one another). To our
knowledge, the study by Hoy and colleagues [25] is the
only published data regarding variation in gut bacteria in
mice shipped from the same vendor over time.
In our efforts to understand how gut microbiota im-
pacts the severity of malaria, we utilized our observation
that mice purchased from different vendors display rela-
tively low or high Plasmodium parasite burdens [18, 26–
28]. Mice purchased from Taconic Biosciences were
consistently used as a source of mice with low parasite
burden. Curiously, we noted a stark change in parasite
burden in Taconic mice, despite ordering from the same
production room, which created considerable disruption
to ongoing experiments. In this study, we demonstrate
that a marked change in gut bacteria occurred within a
defined vendor production suite that impacted experi-
mental reproducibility in two infectious disease models
and a murine tumorigenesis model. These observations
raise the possibility that other investigators may have ob-
served similar deviations within their mouse model sys-
tems. Furthermore, this is a demonstration that mouse
gut microbiota, whether from commercial vendors or in-
house sources, are an important factor to consider for
reproducible, controlled results. Finally, these results
emphasize the need for researchers to fully understand
that variability is possible even when animals are pur-
chased from the same room at the same vendor, and the
need for commercial vendors to educate their customers
about their husbandry practices and health standards.
Ultimately, researchers and vendors should come to-
gether to determine the level of control and reporting
that will aid in efforts to account for potential micro-
biota effects.
Results
Change in the severity of malaria within Taconic mice
correlates with shift in gut bacteria populations
In an effort to avoid variation in gut microbiota, our la-
boratory has specifically ordered C57BL/6NTac mice
from Taconic Biosciences from the production room
Isolated Barrier Unit™ (IBU)15 located at the German-
town, New York facility. Between the years of 2012 and
2016, these mice displayed a relatively low parasite bur-
den following infection with Plasmodium yoelii 17XNL,
with peak parasitemia reaching 10–20% and clearance of
the parasite within 3 weeks post-infection (Fig. 1a, b,
and as published [18, 26]). Surprisingly, between Decem-
ber 2016 and February 2017, there was a profound
change in the parasitemia profile of these mice, where
peak parasitemia in mice obtained from IBU15 post-
2017 consistently reached 50–60% and clearance of
parasite occurred around 4 weeks post-infection (Fig. 1a,
b). In an effort to understand what led to this change, it
was discovered that the IBU15 production room is a
suite of three rooms (IBU001501C, IBU001502C, and
IBU001503C). As it was unknown that IBU15 was a
suite of rooms at the time the experiments were con-
ducted, mice in Fig. 1a cannot be distinguished between
IBU001501C, IBU001502C, and IBU001503C. There is
also a separate C57BL/6N production room
(IBU001703C) at the Germantown, New York facility.
Taconic Biosciences also has a C57BL/6N production
room (IBU050401C) in Cambridge City, Indiana.
C57BL/6N mice from each of these five separate rooms
were obtained to determine if mice displayed similar P.
yoelii parasite burdens. Following P. yoelii infection,
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mice from each of the four rooms from the German-
town, New York facility displayed relatively high parasite
burdens peaking between 30 and 50% with clearance of
P. yoelii occurring between 3 and 4 weeks post-infection
(Fig. 1c, d). In contrast, mice from the Cambridge City,
Indiana facility (IBU050401C) exhibited peak parasitemia
of approximately 5% and cleared the parasite about
2 weeks post-infection (Fig. 1c, d). Hereafter,
IBU001501C, IBU001502C, IBU001503C, IBU001703C,
and IBU050401C will be shortened as IBU1501,
IBU1502, IBU1503, IBU1703, and IBU504, respectively.
Although these data did not explain the temporal change
in malaria severity in IBU15 mice, they did demonstrate
a consistent phenotype in mice from multiple rooms
from the Germantown, New York facility.
We previously demonstrated that distinct gut micro-
biota communities from different mouse vendors impact
the severity of malaria [18]. This led to the hypothesis
that there was a change in gut microbiota in mice from
the IBU15 suite between December 2016 and February
2017. To first test this hypothesis, 16S rRNA gene
sequencing was performed on fecal pellets obtained from
mice ordered from each of the five separate IBUs to de-
termine if differences in gut bacterial communities cor-
related with differences in P. yoelii infection. Alpha
diversity measured with observed taxonomic units
(OTUs) at the species level (total number of OTUs
within a given sample) and Shannon index (considers
both the number of OTUs and the evenness of those
OTUs within the sample) showed that IBU1703 was sig-
nificantly different from the other IBUs (p < 0.001;
Fig. 2a, b). Similarly, observed OTUs were significantly
different between IBU504 vs. IBU1501 and IBU1501 vs.
IBU1502 (p < 0.05) (Fig. 2a). Additionally, beta diversity
(i.e., a comparison of bacteria populations between sam-
ples) measured with Bray-Curtis dissimilarity index
(measures both species richness and their abundance)
and weighted UniFrac distance (measures species rich-
ness, their phylogenetic relatedness and abundances)
showed that all the IBUs were significantly different
from each other except IBU1501 and IBU1503 (p < 0.01;
Fig. 2c, d and Additional file 1, Fig. S1E-F, respectively).
Fig. 1 Temporally discrete P. yoelii parasitemia profiles in Taconic C57BL/6N mice. C57BL/6N mice from Taconic Biosciences were infected with P.
yoelii 17XNL followed by the analysis of parasite burden. a Percent parasitemia was measured in Taconic mice obtained from a single C57BL/6N
production suite, Isolated Barrier Unit™ (IBU15), on the indicated date. Data are from 3 to 5 mice per group.. b Area under the parasitemia curve
(AUC) from a with each symbol representing an individual mouse. c Percent parasitemia in Taconic mice obtained from specific C57BL/6N IBUs.
Data are cumulative results with 8–10 mice per group from two experiments. d AUC from c with each symbol representing an individual mouse.
Data are mean ± S.E. b,d. One-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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Fig. 2 Discrete parasitemia profiles correlate with a shift in Taconic C57BL/6N gut bacteria populations within a defined production suite. Fecal
pellets were collected from mice (n = 8 mice; 4 mice each from two separate shipments) obtained from the indicated Taconic IBUs and subjected
to 16S rRNA gene sequencing. Data were analyzed at species level with a 23,000 sequencing depth per sample. a, b Alpha diversity analysis using
Observed_OTUs (a) and Shannon index (b). Data (mean ± S.E.) were analyzed by the Kruskal-Wallis test. c, d The PCoA plot shows beta diversity
using Bray-Curtis dissimilarity distance (c), and the box and whisker plot shows their statistical significance by pairwise PERMANOVA with 999
permutations between IBUs on the top of vertical columns to IBUs on the X-axis (d). The box end depicts the lower and upper quartiles and the
horizontal line inside the box is the median while points outside the whisker are outliers. The Y-axis shows the Bray-Curtis dissimilarity distance of
IBUs on the X-axis to IBUs on the top of vertical columns. e Cladogram shows differentially abundant bacterial taxa among different IBUs with
respective node color identified using LEfSe analysis. The cutoff for the LEfSe method was p < 0.05 (Kruskal-Wallis test) with LDA score > 4.
*p < 0.05, **p < 0.01, ***p < 0.001
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However, Jaccard distance (measures species richness
but not their abundance) and unweighted UniFrac dis-
tance (measures species richness and their phylogenetic
relatedness but does not consider abundances of the
species) showed that all the IBUs, including IBU1501
and IBU1503, were significantly different from each
other (p < 0.01 for all comparisons except unweighted
UniFrac distance IBU1502 vs. IBU1503, p < 0.05; Add-
itional file 1, Fig. S1A-D). Thus, with the exception of
when species abundance is taken into consideration be-
tween IBU1501 and IBU1503 (Fig. 1d), the data demon-
strate that bacteria communities are different among
these barrier rooms. Interestingly, multiple bacterial taxa
were differentially abundant among the IBUs at different
taxonomic levels (Fig. 2e). Most of the differentially
abundant bacteria were present in IBU1703 (Fig. 2e).
These data support the hypothesis, but only show a cor-
relation between bacteria communities and P. yoelii
parasite burden. Moreover, as these data are from mice
obtained post-2016, they do not provide a direct demon-
stration that there was indeed a change in gut bacteria
populations in IBU15 mice between December 2016 and
February 2017.
Shift in gut microbiota within a Taconic IBU caused
profound alterations in the severity of malaria in mice
To determine whether a discrete temporal shift occurred
in gut microbiota between December 2016 and February
2017 and caused the change in malaria severity within
IBU15 mice, cecal contents from mice before and after
this timepoint were transferred into germ-free mice.
Cecal contents extracted from IBU15 mice in August
2016 (Fig. 1a) were collected and frozen at − 80 °C; of
note, other mice from this shipment had low P. yoelii
parasitemia (Fig. 1a). These are referred to as the “IBU15
Lo” cecal contents. In contrast, mice received from
IBU1501 post-2017 are referred to as “IBU1501 Hi”
mice. Germ-free mice were colonized with cecal con-
tents from either IBU1501 Hi or IBU15 Lo mice. Fecal
pellets were collected from germ-free mice colonized
with IBU1501 Hi or IBU15 Lo as well as control
IBU1501 Hi and IBU504 (low parasitemia control) mice
on the day of P. yoelii infection (Fig. 3a).
Alpha and beta diversity analyses of fecal bacteria pop-
ulations showed that GF+IBU15 Lo had different num-
bers of species and bacteria composition compared to
GF+IBU1501 Hi (Fig. 3b–d). Of note, differences in the
bacteria populations between the two ceca donors,
which represent temporally different and phenotypically
distinct (with respect to P. yoelii parasitemia) mice from
the same IBU, were evident in the principal coordinates
analysis (PCoA) plot (Fig. 3d, box symbols). Collectively,
these results demonstrate that there was a change in gut
bacteria within IBU15 mice after August 2016. As
expected, fecal bacteria compositions in GF+IBU1501 Hi
mice were similar to those in control IBU1501 mice but
were significantly dissimilar to those in GF+IBU15 Lo
mice and control IBU504 mice (p < 0.01; Fig. 3e left
grouping). Likewise, there was a significant difference in
bacteria compositions in GF+IBU15 Lo mice and control
IBU1501 Hi mice (p < 0.01; Fig. 3e second from left
grouping). Although bacteria populations from
GF+IBU15 Lo and control IBU504 mice are relatively
similar to one another compared to the GF+IBU1501 Hi
and control IBU1501 mice, indicated by their close prox-
imity to one another on the PCoA plot (Fig. 3d), the
bacteria populations were also significantly different be-
tween GF+IBU15 Lo and control IBU504 (p < 0.01;
Fig. 3e second from left grouping). Moreover, most of
the differentially abundant bacterial taxa were present in
IBU504, which is consistent with these mice originating
from a completely different facility (Fig. 3f). In support
of the hypothesis that changes in gut bacteria compos-
ition in IBU15 mice caused the change in P. yoelii para-
sitemia, germ-free mice colonized with cecal content
from IBU1501 Hi mice (GF+IBU1501 Hi) displayed high
parasitemia similar to the control IBU1501 Hi mice,
while germ-free mice colonized with cecal content from
IBU15 Lo mice (GF+IBU15 Lo) had low parasitemia
similar to control IBU504 mice (Fig. 3g, h). These data
provide compelling evidence that a shift in gut micro-
biota in mice within the IBU15 production suite at the
juncture of 2016 and 2017 profoundly altered the sever-
ity of malaria in these mice. It is currently unclear
whether the observed change in gut bacteria (Fig. 3d–f)
was responsible for the change in malaria severity or
whether changes in other gut microbiota constituents
(viruses, fungi, archaea, etc.) also impacted the severity
of malaria.
Differences in gut microbiota in Taconic mice impact
reproducibility of additional murine model systems
These results led to the hypothesis that other model sys-
tems may also have been impacted by the change in gut
microbiota within IBU15 mice. To test this possibility,
mice were obtained from Taconic rooms IBU504 and
IBU1501. Of note, this is not a direct comparison of
Taconic IBU15 mice before and after the juncture of
2016 and 2017 that profoundly altered the severity of
malaria in these mice owing to limitations in stored ceca
samples from IBU15 mice pre-2017 (temporal shifts).
The effects of different gut microbiota composition be-
tween IBUs (spatial change) were tested on two disease
models. Following Salmonella enterica serovar Typhi-
murium infection, mice from Tac IBU504 had higher
levels of S. typhimurium in feces on day 1 post-infection
compared to Tac IBU1501 mice, while no differences
were detected on days 4 and 6 in the feces or in the
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spleen on day 7 post-infection in these three groups of
mice (Fig. 4a, b).
A similar trend was observed in LSL-KrasG12D (Kras)-
driven lung adenocarcinoma. Kras mice were treated
with an antibiotic cocktail to deplete native microbiota.
Mice were then gavaged with cecal microbiota from
IBU504 (low parasitemia) and IBU1501 (high parasit-
emia) to recapitulate differential gut microbiotas be-
tween Taconic facilities. Finally, the mice were infected
with Adeno-Cre virus to induce spontaneous lung
Fig. 3 Shift in gut bacteria populations within Taconic C57BL/6N production suite causes differential severity of malaria. a Schematic of the
experimental design. IBU1501 Hi = shipment of IBU1501 mice post-2017, IBU15 Lo = IBU15 mice from same shipment on August 2016 as reported
in Fig. 1a, b. The cecum from the August 2016 mice (IBU15 Lo) had been removed and stored at − 80 °C. Ceca microbiota from IBU1501 Hi and
IBU15 Lo were gavaged to GF mice in SPF facility and after 1 week were infected with P. yoelii 17XNL. The experiments were independently
performed twice. b, c Fecal bacterial populations were profiled with alpha diversity using Observed_OTUs (b) and Shannon index (c). Data
(mean ± S.E.) were analyzed by the Kruskal-Wallis test. d The PCoA plot shows beta diversity using the Bray-Curtis distance. e Statistical
significance of beta diversity. The box end depicts the lower and upper quartiles and the horizontal line inside the box is the median while
points outside the whisker are outliers. The Y-axis shows the distance of IBUs on the X-axis to IBUs on the top of vertical columns. Statistical
significance is compared between IBUs on top of vertical columns to IBUs on the X-axis by pairwise PERMANOVA with 999 permutations. f
Cladogram shows differentially abundant bacterial taxa among different groups with respective node color identified using LEfSe analysis. The
cutoff for the LEfSe method was p < 0.05 (Kruskal-Wallis test) with LDA score > 4. g Parasitemia of mice on the indicated day post-Py infection. h
Parasitemia AUC days 5–27 from f. Data are cumulative results with 9–10 mice per group from two experiments with each symbol representing
an individual mouse. Data (mean ± S.E.) were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. **p < 0.01,
***p < 0.001, ****p < 0.0001
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Fig. 4 (See legend on next page.)
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adenocarcinoma (Fig. 4c and Additional file 2, Fig. S2A).
Alpha and beta diversity (Bray-Curtis and weighted Uni-
Frac) analyses showed no difference in gut bacterial
composition between naïve Kras (Naïve-Kras) mice and
Kras mice that received naïve Kras fecal microbiota
(Kras-FMT) (Fig. 4d–f and Additional file 2, Fig. S2B, G,
and H). Yet, beta diversity measured using Jaccard dis-
tance and unweighted UniFrac distance showed minor
but significantly different gut bacterial composition be-
tween Naïve-Kras and Kras-FMT (Additional file 2, Fig.
S2C-F). Kras mice that had IBU504 and IBU1501 fecal
microbiota transplant (IBU504-FMT and IBU1501-FMT,
respectively) had distinct gut microbiota composition
compared to other groups (p < 0.01) (Fig. 4e, f and Add-
itional file 2, Fig. S2C-H). An analysis of lung tumor
burden demonstrated that only 1501-FMT developed
significantly higher lung tumor burden compared to the
other groups (p < 0.05, Fig. 4g). Further analysis demon-
strated that naïve-kras mice (i.e., lower lung tumor
burden) were associated with Akkermansia, Prevotella,
and Parasutterella while 1501-FMT (i.e., higher lung
tumor burden) were associated with Turibacter and
Stomatobaculum bacterial genera (Fig. 4h). Thus, dif-
ferences in Taconic mouse gut microbiota sourced
from different colonies also impacted the development
of lung tumors. DSS-induced colitis has been shown
to be impacted by gut microbiota [29], and minor dif-
ferences were also noted between IBU504 and
IBU1501 mice treated with DSS in body weight loss,
though these differences were less pronounced (Add-
itional file 3, Fig. S3). Although these latter mouse
models do not exhibit as drastic differences like those
seen between Taconic mice infected with P. yoelii, the
collective data demonstrate that changes in gut
microbiota, even within a specific vendor, can impact
experimental reproducibility and represent a critical
variable of which the scientific community needs to
be aware.
Discussion
To our knowledge, this is the first study to systematically
report a shift in gut microbiota within genetically identi-
cal mice ordered from the same production suite from a
specific vendor over time and the effect this shift in gut
microbiota had on an experimental model system. Al-
though this unexpected shift in gut microbiota nega-
tively impacted our murine malaria model system, it is
important to stress that it is abundantly clear that com-
mercial providers of mice implement robust standard
operating procedures to provide the scientific commu-
nity with mice that are as homogenous over time as is
technically and practically feasible. This is evident by the
reproducibility of many model systems from many labs
over time. Indeed, we have observed consistent pheno-
types in P. yoelii parasite burden from multiple vendors
for the 7+ years that we have studied the impact of gut
microbiota on the severity of malaria. Still, the results
presented in this report highlight that despite these
rigorous practices, gut microbiota in mice can change
within commercial vendors and that these changes can
have profound implications.
It is clear based on the exponential growth in gut
microbiota research over the past decade and the ever-
increasing number of diseases and host processes that
are impacted by gut microbiota that properly controlling
for variations in gut microbiota can no longer be
avoided. How should the scientific community respond
to these realities? This likely involves responses by both
commercial vendors and scientists. Regarding commer-
cial vendors, they should raise the awareness and re-
sponsibility to at a minimum continue to provide
transparency on the realities and limitations of commer-
cial animal production. Commercial animal suppliers
produce animals utilizing processes that prioritize the
maintenance of high genetic quality and health standards
[30, 31]. In order to provide animals that are at mini-
mum specific pathogen free, vendors have exclusion
(See figure on previous page.)
Fig. 4 Difference in Taconic gut bacteria populations impacts reproducibility in infectious (Salmonella) and non-infectious (lung tumor) disease
models. a C57BL/6N mice from the indicated IBUs at Taconic were infected with S. enterica serovar Typhimurium. S. enterica serovar Typhimurium
bacterial burden was determined by measuring the number of colony-forming units (CFU) per gram of feces (a) or spleen (b) on the indicated
day post-infection. Each symbol represents an individual mouse. Data (mean ± S.E.) are cumulative results with 7–8 mice per group from two
experiments and were analyzed by the Mann-Whitney test. c Schematic of the lung tumor model. Two independent experiments were
conducted with n = 8 per group. Kras mice were treated with antibiotics, received fecal microbiota transplantation (FMT) from naïve mice having
low or high Py parasite burden, and infected with Adeno-cre virus for the spontaneous development of lung tumor. d–f Fecal pellets were
collected and subjected to 16S rRNA gene sequencing. Data were analyzed at 19,000 sequencing depth per sample. d Alpha diversity using
Observed_OTUs. Data (mean ± S.E.) were analyzed by the Kruskal-Wallis test. e The PCoA plot shows beta diversity using the Bray-Curtis distance.
f Bray-Curtis dissimilarity index between indicated samples. The box end depicts the lower and upper quartiles and the horizontal line inside the
box is the median while points outside the whisker are outliers. The Y-axis shows the distance of IBUs on the X-axis to IBUs on the top of vertical
columns. Statistical significance is compared between IBUs on top of vertical columns to IBUs on the X-axis by pairwise PERMANOVA with 999
permutations. g Lung tumor burden in different groups of Kras mice as shown in c. Data (mean ± S.E.) were analyzed by the Kruskal-Wallis test
and post hoc analysis with Dunn’s test. h Cladogram shows differentially abundant bacterial taxa between two IBUs having significantly different
lung tumor burden with respective node color calculated using LEfSe analysis. The cutoff for the LEfSe method was p < 0.05 (Kruskal-Wallis test)
with LDA score > 4. *p < 0.05, **p < 0.01, ***p < 0.001
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criteria that stock are maintained against. Through pro-
cesses developed to exclude organisms, it is likely that
microbial diversity is restricted to varying degrees across
all providers based on the specific health standard and
husbandry practices used. To prevent genetic drift, peri-
odic genetic refreshment is required whereby breeder
animals are replaced using foundation colony stock with
pedigreed genetics. This process also provides an oppor-
tunity to alter the microbial community of a mouse col-
ony maintained under barrier conditions. It also suggests
that a system of uniform health standards/profiles
should be implemented across vendors to better support
the scientific community. Animals of higher health sta-
tus are generally housed in more controlled environ-
ments such as individually ventilated caging (IVCs) or
even isolators. Furthermore, some commercial providers
are developing services to generate and maintain gnoto-
biotic mouse models that can be utilized to address con-
cerns relating to reproducibility and predictability. These
options aid in reducing some microbiota shifts, but do
not eliminate the possibility of change. Another possibil-
ity, albeit a more drastic measure, is for commercial ven-
dors to routinely perform gut microbiota analysis of
mice within production rooms and communicate the re-
sults of those analyses to the scientific community in a
clear and meaningful way. This would introduce many
challenges including the feasibility of such an undertak-
ing, the frequency of gut microbiota analysis, and how to
communicate those results in a manner that is meaning-
ful to a non-microbiome expert.
Regarding a response from scientists, at the very least,
these results emphasize the importance of reporting not
only where mice were purchased from, but also the bar-
rier room where those mice originated from. It is pos-
sible that many researchers are unaware of the
numerous locations within a single vendor from which
their mice may be originating, and if they are consist-
ently coming from the same barrier room over time. Re-
searchers also need to be mindful of the housing and
husbandry methods in their own facilities. Publishers
could help facilitate the consistent and uniform com-
munication of mouse husbandry details through the
inclusion of a mouse husbandry reporting standard
that includes vendor name, mouse strain, barrier
room, and institutional husbandry (type of water, diet
details, bedding, light cycle, etc.). Implementation of
this reporting in manuscripts will provide critical in-
formation to the scientific community that may im-
prove experimental reproducibility within a lab over
time, as well as the efforts of others to repeat the
published studies. Do the realities highlighted in this
report mean that researchers need to freeze feces
from study animals and associate the next study co-
hort with the same microbiota? While it may sound
drastic, it may be what is needed to generate repro-
ducible data in cases where gut microbiota are par-
ticularly impactful to study outcomes.
Conclusion
These data demonstrate that gut microbiota can
undergo profound changes in commercial laboratory
mice within specific vendor barrier rooms that have the
potential to alter experimental reproducibility. Shared
responsibility between vendors and scientists will allow
more reproducible microbiome experiments. Vendors
should provide scientist with mice gut microbiome pro-
file in a timely manner. Scientist should provide all the
necessary details regarding the source of mice including
isolated breeding unit. In sum, we hope that introduc-
tion and application of these practices, to some extent,
will re-build confidence of both the public and scientists
themselves, in the scientific process and our endeavors




Female 6-week-old C57BL6/N mice were purchased
from the indicated barrier rooms at Taconic Biosciences
(Tac) (Hudson, NY) and allowed to acclimate for 1 week
before collecting fecal pellets or cecal content and start-
ing infections. Mice were kept on NIH-31 Modified
Open Formula Mouse/Rat Irradiated Diet (Envigo item#;
7913, Huntingdon, UK) and autoclaved, non-acidified,
reverse osmosis water. Mice were kept on a 12-h light/
dark cycle from 6 AM to 6 PM and 6 PM to 6 AM, re-
spectively. All animal handling and experimentation
were reviewed and approved by the University of Louis-
ville Institutional Animal Care and Use Committee
based on the recommendations of the Guide for the
Care and Use of Laboratory Animals of the National In-
stitutes of Health. Mice were euthanized by carbon diox-
ide asphyxiation.
Plasmodium infection
C57BL/6N mice were injected intravenously with 1 × 105
red blood cells (RBCs) infected with Plasmodium yoelii
17XNL diluted in 200 μL of saline, passaged from donor
infected mice. Parasitemia, the percentage of infected
red blood cells, was monitored using flow cytometry be-
ginning on day 5 p.i. and continuing every other day
until clearance of the parasite. Blood was collected from
the tails of infected mice. From each mouse, ~ 5 μL of
whole blood was diluted in 100 μL of cold PBS, fixed in
0.00625% glutaraldehyde, and then stained. The staining
panel included CD45.2-APC (clone 104; Biolegend, San
Diego, CA), Ter119-APC/Cy7 (clone TER-119; Biole-
gend, San Diego, CA), dihydroethidium (MilliporeSigma,
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St. Louis, MO), and Hoechst 33342 (MilliporeSigma, St.
Louis, MO); samples were then resuspended in flow cy-
tometry buffer and analyzed. Infected red blood cells
were identified by first gating on single cells followed by
gating on Ter119+CD45.2− red blood cells. Infected red
blood cells were identified as dihydroethidium+Hoechst
33342+.
Colonization of germ-free mice
Genetically identical germ-free (GF) C57BL/6 mice were
ordered from Taconic Biosciences (Hudson, NY). GF
mice were gavaged with cecal content from the indicated
donor inside a laminar flow hood. Cecal content, either
previously frozen or freshly extracted, was extruded out
of the ceca and gently mixed for ~ 30 s in 5 mL 0.9%
sterile saline (Teknova, Hollister, CA). Each mouse re-
ceived 200 μL of diluted cecum material. After gavage,
mice were conventionally housed as described above.
Salmonella infection
Salmonella enterica serovar Typhimurium 14028 was
grown overnight in Luria-Bertani (LB) medium (BD,
Sparks, MD) with carbenicillin (50 μg/mL; Corning,
Corning, NY) on a shaking rack at 200 RPM at 37 °C.
One hundred microliters of overnight growth was trans-
ferred to 10mL LB medium and grown to OD600 = 0.1.
The subculture was washed once with 1X phosphate-
buffered saline (PBS), and colony-forming unit (CFU)
was adjusted to ~ 5 × 105 CFU/200 μL in 1X PBS. CFU
of inoculum was counted before and end of gavage to
see the effect of static container sitting in the hood. No
statistical difference in CFU of inoculum was seen. Each
mouse was gavaged with 200 μL of inoculum around 2
PM for both trials. Inoculum gavage in IBU504 mice
was followed by 1BU1501 mice for both trials. For Sal-
monella load in feces, one or two fresh fecal pellets were
collected on indicated days in a sterile cryogenic vial on
ice, weighed, homogenously mixed in 1X PBS, and
plated on Brilliant Green agar (Sigma-Aldrich, St. Louis,
MO) with carbenicillin (50 μg/mL). The plates were in-
cubated for 18 h, and pink colonies were counted. For
Salmonella load in the spleen, mice were euthanized at
the end point (day 7 post-infection) and the spleen was
harvested aseptically in 3 mL sterile 1X PBS and
weighed. Spleens were homogenized and plated on LB
agar plates with carbenicillin (50 μg/mL). Plates were in-
cubated overnight, and colonies were counted.
Kras-driven lung adenocarcinoma
LSLKras (B6.129S4-Krastm4Tyj/J) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME) and
bred in a specific pathogen-free facility at the University
of Louisville School of Medicine. Eight mice were allo-
cated to each group (total 4 groups). Three groups of
mice received an antibiotic cocktail (ampicillin (Sigma-
Aldrich, St. Louis, MO), gentamicin (Corning, Corning,
NY), metronidazole (Spectrum, Gardena, CA), and neo-
mycin (Goldbio, St. Louis, MO) at concentration of 0.5
mg/mL, and vancomycin (VWR Chemicals, Sanborn,
NY) at 0.25 mg/mL in drinking water for 3 weeks. Drink-
ing water was changed weekly. Antibiotic treatment was
ceased followed by fecal microbiota transplants (FMT)
on 3 consecutive days. Fecal pellets were collected from
each mouse prior to adenoviral-cre (Viral Vector Core
Facility, University of Iowa) infection, and lung histo-
logical slides were done as described by Li et al. [32].
Briefly, adenoviral infection was performed intranasally
in anesthetized mouse with isoflurane at 2.5 × 107 PFUs
per mouse in two 30-μL installations. Mice were housed
as described above for 6 weeks to allow for the develop-
ment of spontaneous lung adenocarcinoma. After 6
weeks, lungs were harvested for histological slides to
quantify the tumor load. Briefly, lungs were harvested
and infused with 10% neutral buffered formalin (Leica
Biosystems) for 18 h, embedded in paraffin, and serially
sectioned. Six representative sections were taken
throughout the lung to provide representative samples
and stained with H&E for microscopic analysis.
Histological analysis
Image sections were captured with the Aperio Scan-
Scope XT Slide Scanner (Aperio Technologies, Vista,
CA) system with a × 20 objective, and tumor burden was
quantified with QuPath v0.1.2 software as described in
the QuPath manual for H&E stain [33]. Briefly, the
image file was opened as image type H&E stain. Random
trees classifier was interactively trained to distinguish be-
tween healthy and hyperplasia at the cellular level. The
same classifier was used for all the slides. The results
from QuPath were comparable to the manual score
using Spectrum WebScope (Spectrum version
10.1.5.2028). Percent tumor area (tumor burden) was
calculated as the ratio of tumor area to total lung area
per section, and all sections from a single mouse were
averaged to get tumor area per mouse.
DSS-induced colitis
Mice from Tac IBU504 and Tac IBU1501 were adminis-
tered 3% colitis grade DSS (MP Biomedicals, Solon, OH)
in drinking water for 6 days to induce acute colitis,
followed by cessation of treatment and return to conven-
tional water for a 14-day recovery period. Control mice
were on conventional water for the duration of the ex-
periment. All mice were monitored for mortality and
weight throughout treatment and recovery periods. The
ceca and colon were harvested at the end of the experi-
ment from control and DSS-treated mice. Fat was re-
moved from colons followed by length measurements.
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Colons were then washed with 1X PBS followed by
weight measurements.
Gut microbiota analysis
Mouse fecal pellets and cecal contents were collected
and flash frozen in liquid nitrogen followed by storage at
− 80 °C. DNA was extracted using the QIAamp Power-
Fecal DNA kit (QIAGEN, Germantown, MD) according
to the manufacturer’s instructions. DNA samples were
shipped overnight on ice to the Genome Technology
Access Center at Washington University (GTAC, St.
Louis, MO) for sequencing and analysis using the Mul-
tiple 16S Variable Region Species-Level IdentificatiON
(MVRSION) algorithm [34]. Observed taxonomic unit
(OTU) table and phylogenetic tree file generated by
MVERSION were imported inside QIIME2 [35] for
visualization and statistical analyses. Alpha and beta di-
versity analyses for different IBUs (Fig. 2) and germ-free
experiment (Fig. 3) were performed at 23000 sequencing
depth per sample, and for lung adenocarcinoma (Fig. 4
and Additional file 2, Fig. S2), these were performed at
19000 sequencing depth per sample at the species level.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 7 software (GraphPad Software, La Jolla, CA,
USA). For all analyses, the alpha was set at 0.05. For area
under the parasitemia curve (AUC) analyses, the trapez-
oidal rule was used for Eq. (1):
AUC t1‐t‐lastð Þ ¼ Σ pi þ piþ1
  tiþ1−tið Þ=2 ð1Þ
where “p” is the percent parasitemia at the designated
time point “t” [36]. Specific statistical tests are described
in the figure legends.
Differentially abundant bacterial taxa were identified
using the linear discriminant analysis (LDA) effect size
(LEfSe) method [37]. The cutoff values were p < 0.05
(Kruskal-Wallis test) with LDA score > 4.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12915-020-00810-7.
Additional file 1: Figure S1. Bacterial beta diversity analysis between
mice from different Taconic IBUs. Same samples and analysis as in Fig. 2.
PCoA plot shows beta diversity using Jaccard distance (A), Unweighted
(C) UniFrac and (E) Weighted UniFrac distance and their statistical
significance is shown by (B), (D) and (F), respectively. Box end depicts
lower and upper quartile and horizontal line inside box is median while
points outside whisker are outliers. Y-axis shows distance of IBUs on X-
axis to IBUs on the top of vertical columns. Statistical significance is com-
pared between IBUs on top of vertical columns to IBUs on the X-axis by
pairwise PERMANOVA with 999 permutations. * = p < 0.05, ** = p < 0.01.
Additional file 2: Figure S2. Effect of differential gut microbiota from
Taconic IBUs on lung tumor model. A, Parasitemia of mice from IBU504
and IBU1501 shipments that were used as donor for fecal microbiota
transplantation in naïve Kras mice. B-H, Gut microbiota composition of
Kras mice that received distinct gut microbiota as described in Fig. 4. B,
Alpha diversity using Shannon index. Data (mean ± S.E.) were analyzed by
Kruskal-Wallis test. PCoA plot shows beta diversity using Jaccard distance
(C), Unweighted UniFrac (E) weighted UniFrac distance (G); and statistical
significances are shown by (D), (F), (H), respectively. Box end depicts
lower and upper quartile and horizontal line inside box is median while
points outside whisker are outliers. Y-axis shows distance of IBUs on X-
axis to IBUs on the top of vertical columns. Statistical significance is com-
pared between IBUs on top of vertical columns to IBUs on the X-axis by
pairwise PERMANOVA with 999 permutations. * = p < 0.05, ** = p < 0.01. I,
Representative H&E section of lung from naïve-Kras and IBU1501-FMT
groups analyzed using QuPath. Green is healthy area while red is hyper-
plastic area.
Additional file 3: Figure S3. Differences in Taconic gut microbiota had
minimal impact on DSS-induced colitis. A, Schematic of experimental de-
sign. Mice from IBU504 and IBU1501 received 3% DSS in drinking water
for 6 days and switched to regular water for recovery. Mice were moni-
tored for weight and mortality till the end of recovery period (14 days)
and colon collected at the end. N = 5 for control and N = 10 for DSS
treated mice. B, Percent survival. Statistical analyses were performed with
Log-rank (Mantle-Cox) test. C, Weight gain. Unpaired t-tests were used
compare % of initial body weight at each time point between the DSS
treated and control mice. Colon weight (D) and colon length (E) of sur-
viving mice at the end of recovery period. Statistical analyses were per-
formed with ordinary one-way ANOVA followed by Tukey’s multiple
comparisons test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p <
0.0001.
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